Skip to main content
Premium Trial:

Request an Annual Quote

Precision Oncology Resources: Recent webinars

Jun
23
2022

Sponsored by Antylia Zeptometrix

Best Practices for Maintaining Quality in Molecular Diagnostic Testing

Molecular diagnostics has quickly become one of the leading global technologies for infectious disease testing. As such, clinicians and physicians rely on the results generated from these tests for accurate patient diagnoses. The field is constantly growing and evolving to meet the demands of infectious disease testing, but what remains constant is the importance for laboratories to maintain rigorous quality management practices, including quality control, to help ensure reliable test results.

With multiple regulatory and accreditation bodies like ISO, CLIA, CAP, and CLSI weighing in on good laboratory and quality practices, it can be challenging to implement a quality management system for your laboratory. This webinar will elucidate the current landscape of considerations for implementing a quality system in laboratories running molecular diagnostic assays, including quality controls.

At the end of this webinar, attendees will be able to:

  1. Describe the relevant regulatory and quality system management principles as they apply to laboratories running molecular diagnostic tests.
  2. Design appropriate quality control strategies for molecular/PCR-based testing methodologies.
  3. Identify tools to help implement effective quality management of molecular diagnostic tests.

Sponsored by

ZeptoMetrix_ASC.jpg
Jun
21
2022

Sponsored by Illumina

DNA Methylation Dynamics and Dysregulation Delineated by High-Throughput Profiling in the Mouse

In this webinar, Peter W. Laird, professor at the Van Andel Research Institute, will discuss the development of a mouse DNA methylation array that contains 296,070 probes representing the diversity of mouse DNA methylation biology. Laird will present a comprehensive validation of this array platform and discuss the applications for comparative epigenomics, genomic imprinting, epigenetic inhibitors, PDX assessment, backcross tracing, and epigenetic clocks. This Infinium Mouse Methylation BeadChip (version MM285) is widely accessible to the research community and will accelerate high sample-throughput studies in this important model organism.

Laird and colleagues have dissected DNA methylation processes associated with differentiation, aging, and tumorigenesis. Notably, the team found that tissue-specific methylation signatures localize to binding sites for transcription factors controlling the corresponding tissue development. Age-associated hypermethylation is enriched at regions of Polycomb repression, while hypomethylation is enhanced at regions bound by cohesin complex members. ApcMin/+ polyp-associated hypermethylation affects enhancers regulating intestinal differentiation, while hypomethylation targets AP-1 binding sites.

Sponsored by

Jun
16
2022

Sponsored by Mission Bio

Bringing a New Standard of Clarity to Solid Tumor Research With Single-Cell Genomics

A major challenge to combating cancer is the dynamism and inherent heterogeneity contributing to the disease's onset, progression, and relapse. In the enormous efforts to identify the factors underlying these factors, bulk sequencing is widely used, but the need for unmasking the underlying genetic diversity across cell populations remains unmet.

Single-cell DNA sequencing can be used to interrogate clonal mosaicism and neoplastic transformation, metastatic dissemination, and therapeutic resistance with its ability to co-analyze SNVs and CNVs at the single-cell level in a scalable manner. As a tool for probing clonal architecture and evolution, researchers can identify zygosity, mutational co-occurrence, and rare mutations in individual cells.

Jorge Reis-Filho of Memorial Sloan Kettering Cancer Center will share the strategies for characterizing intratumor heterogeneity and evolutionary trajectories in cancers at the single-cell level and present his latest findings in breast cancer research.

This webinar will also present the latest advances in single-cell DNA sequencing, including pre-designed solid tumor DNA panels, single-cell CNV analysis workflow, and nuclei isolation protocols enabling solid tumor researchers to access this technology.

Attendees will:

  • Learn how single-cell DNA sequencing can bring a new level of clarity to research in solid tumors, such as breast cancer, by providing insights into the clonal architecture, mutation co-occurrence, and rare mutations driving tumor progression and therapy resistance.
  • Discover the science behind the Tapestri single-cell sequencing platform.
  • Hear about case studies and implementation considerations, including cell and nuclei prep, panel design, and analysis.

Sponsored by

field_file_image_alt_text_value
May
23
2022

Sponsored by Millipore Sigma

Enabling Earlier Cancer Detection with Glycosaminoglycan Profiling

Swedish diagnostics company Elypta aims to prevent cancer mortality by enabling earlier cancer detection. In this video, members of the Elypta leadership team — Chief Executive Officer, Karl Bergman, and Vice President of R&D, Karin Mattsson — discuss innovation in glycosaminoglycan (GAG) extraction and measurement as novel biomarkers for cancer and describe how working closely with Merck as a contract manufacturing partner has enabled Elypta to produce the first standardized extraction kit for full-spectrum human GAG quantification in body fluids.

Sponsored by

field_file_image_alt_text_value
May
19
2022

Sponsored by Invivoscribe

Next-Generation Sequencing of Immunoglobulin Genes in Lymphoid Malignancies

The study of B-cell receptor rearrangements has impacted a myriad of fields in medicine, including oncology, immunology, and infectious disease. In cancer, lymphoid malignancies harbor clonal rearrangements that can aid in the initial recognition of lymphoma. Next-generation sequencing of the immunoglobulin genes has expanded our understanding of B-cell biology and has introduced new considerations for clonality assessment. In this session, Rena Xian of Johns Hopkins School of Medicine will review the genes involved, compare sequencing techniques, and illustrate special considerations related to immunoglobulin sequencing.

During this webinar, Rena Xian will:

  • Identify genes targeted for clonality assessment in B-cell malignancies.
  • Compare sequencing techniques used for immunoglobulin genes.
  • Describe pre-analytical variables that impact immunoglobulin sequencing.
  • Contrast clonality analysis by next-generation sequencing to traditional non-sequencing methods.

Sponsored by

Apr
27
2022

Sponsored by Grail

Multi-Cancer Early Detection: Implementation Considerations for Health Systems

The earlier cancer can be detected, the higher the chance of survival. Currently, nationally recognized medical organizations only recommend routine screening tests for a few single cancers such as breast, colorectal, lung, and cervical. As a result, three out of four invasive cancers do not have recommended screening tests, with the majority of cancers being diagnosed too late when outcomes are often fatal, and costs are high.

In this presentation, Lincoln Nadauld, chief of precision genomics at Intermountain Healthcare, will discuss how Intermountain plans to offer Galleri, a multi-cancer early detection test shown to detect a cancer signal across more than 50 cancers with a simple blood draw, to its eligible employee population. Nadauld will talk about why early detection is an important initiative for Intermountain, the strategies and considerations to implement a multi-cancer screening test within a health system, and why providing a multi-cancer test can be a valuable benefit to employees. 

Attendees will:

  • Gain knowledge on how offering an early detection blood test may help differentiate a health system.
  • Discover the science and clinical validation behind the Galleri test.
  • Learn about implementation considerations, including PCP training, post-positive workups, and billing.
  • Assess how providing a multi-cancer test can benefit employees.

Sponsored by

Grail
Apr
20
2022

Sponsored by VolitionRx

Novel Proteomics Approach to Epigenetic Profiling of Circulating Nucleosomes

Epigenetic biomarkers are emerging as tools for the early detection of various diseases including cancer. However, to date, tools to investigate candidate epigenetic biomarkers directly from patient blood for diagnosis or patient stratification are limited. Mass spectrometry is a powerful solution for biomarker discovery, but the high complexity of blood, along with the abundance of blood proteins, presents significant challenges for using mass spectrometry as a discovery tool.

Volition has developed a new method for detecting and quantifying circulating nucleosomes and their associated modifications in plasma samples. This method is based on the capture of intact circulating nucleosomes using a newly developed immunoprecipitation method followed by liquid chromatography coupled with tandem mass spectrometry (Nu.Q Capture-MS).

To identify histone post-translational modification signatures of circulating nucleosomes and subsequently discover new biomarkers, Volition, working in conjunction with Axel Imhof of EpiQMAx, implemented this innovative method in a series of pilot studies utilizing plasma samples from cancer patients (colorectal cancer, non-Hodgkin’s lymphoma, lung cancer) and healthy controls.

In this session, Imhof will introduce the Nu.Q Capture-MS technique, outline findings from the pilot studies, and highlight how Nu.Q Capture could be deployed as an upstream blood sample processing step to facilitate the discovery of new biomarkers. Terry Kelly, chief innovation officer at Volition will outline how the technique could add to Volition’s epigenetic toolkit and explain how the company works with other organizations, like EpiQMAx, through its Nu.Q Discover initiative.

Sponsored by

VolitionRx
Mar
24
2022

Sponsored by LevitasBio

Single-Cell Genomics at Memorial Sloan Kettering’s Single-Cell Analytics Innovation Laboratory

The Single-cell Analytics Innovation Laboratory (SAIL) is a platform for cutting-edge molecular profiling and data analysis, serving more than 80 basic and translational research laboratories in the Memorial Sloan Kettering (MSK) community. The lab offers researchers the ability to profile a range of tissue sources at cellular resolution, from animal and cell-based model systems to diverse tumor types, biopsied by various means from the clinic. These approaches are providing insight into cancer-related questions around immunity, tumor plasticity, metastasis, regeneration, wound healing, and immunotherapy. SAIL’s mission is to assimilate emerging technologies in the rapidly advancing fields of single-cell sequencing and imaging-based profiling, in addition to providing robust analytical solutions. SAIL hosts a dedicated computational team that benchmarks new tools and generates pipelines to support an expanding set of technologies and data modalities.

In this webinar, Ronan Chaligné, director of the Single Cell Research Initiative at MSK, will share common challenges that he has encountered when building a clinical sample cohort.  He will speak to different technologies that have been adopted over the years to serve the needs of the Single Cell Research Initiative, including the use of levitation technology as an alternative to fluorescence-activated cell sorting (FACS).

Sponsored by

LevitasBio
Mar
22
2022

Sponsored by PGDx

Therapeutic Options from RAS/MEK Pathway Alterations

This webinar is part four of our four part virtual molecular tumor board series.

In this session, our expert panelists will review patient cases in which genomic profiling has identified activating mutations in the RAS or MEK pathways.

Molecular alterations in growth factor cell signaling pathways have been observed for most cancers and have led to novel treatment strategies. These pathways are often influenced by activating mutations in the RAS family and/or MEK-mediated signaling. There are now inhibitors of MEK and RAS family members (including the KRAS G12C mutation) with emerging clinical treatment strategies using novel combinations.

Clinical challenges for oncologists related to interpretation of these findings have increased as they try to keep up with the therapeutic options, specifically, when to apply them, and how to prioritize RAS/MEK related genes in the context of other alterations that are revealed in patients' comprehensive genomic profiling reports.

Our panel will address these challenges within the context of specific clinical cases. The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

Sponsored by

PGDx
Mar
08
2022

Sponsored by PGDx

Impact of Structural Variants and Co-Occurring Variants on Cancer Therapy Prioritization

This webinar is part three of the four part virtual molecular tumor board series.

In this session, our expert panelists will review patient cases in which genomic profiling has identified structural variants with possible clinical relevance.

Improvements in nucleic acid sequencing technology have made the routine detection of structural alterations such as gene fusions, amplifications, and genomic instability signatures possible. In particular, the clinical relevance of gene fusions has expanded, resulting in both FDA-approved and clinically supported treatment options. Additionally, the increased utilization of comprehensive genomic analyses has the potential to inform a broad range of co-occurring somatic and germline alterations that may be associated with hereditary disease, therapeutic selection, and resistance to treatments.

However, this technological progress has increased clinical challenges for oncologists, as they try to keep up with therapeutic opportunities and understand how to prioritize treatment options amid other biomarker-informed therapies that could also potentially benefit patients based on their comprehensive genomic profiling results.

Our panel will address these challenges and opportunities within the context of specific clinical cases. The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

Sponsored by

PGDx
Mar
03
2022

Sponsored by LGC SeraCare Life Sciences

Understanding and Clarifying the Complexities of HRD Measurements in Cancer

Homologous recombination DNA repair deficiency (HRD) creates a permanent genomic scar in cancer cells for many tumor types. Furthermore, HRD is a response biomarker for poly (ADP-ribose) polymerase inhibitors (PARPi) effective therapy. Consequently, HRD measurement has the potential to improve cancer therapy as evidenced by over 100 clinical trials that include HRD today. However, measuring and standardizing HRD quantitation is not straightforward. HRD measurements may include germline and somatic mutation testing, a measure of hypermethylation, and metrics of genomic instability including loss of heterozygosity, telomeric-allelic imbalance, and large-scale genomic rearrangements. This webinar brings together academic, clinical, IVD, and pharmaceutical experts in the clinical genomics and therapeutics fields to discuss the promises and challenges of HRD measurement for disease management. 

Our panelists on this session will be Ravindra Kolhe, M.D., Ph.D., FCAP, Vice-Chairman of Pathology, Associate Dean for Translational Research Medical College of Georgia at Augusta University and Associate Director for Genomics at Georgia Cancer Center, John Jiang, Ph.D., Senior Director of Medical Affairsat Illumina, David Fabrizio Ph.D., Vice President, Translational Strategy at Foundation Medicine, and Yves Konigshofer Ph.D., Director, Technology Development at LGC Clinical Diagnostics.

Sponsored by

field_file_image_alt_text_value
Feb
24
2022

Sponsored by Thermo Fisher Scientific

Application of Chromosomal Microarray Analysis in Oncology

Chromosomal microarray analysis (CMA) is a first-tier molecular cytogenetics test in the constitutional field helping to identify genetic causes of developmental delay, autistic spectrum disorders, or intellectual disability. CMA also plays a significant role in oncology where whole-genome sequencing or whole-exome sequencing are not yet offered as routine tests or when next-generation sequencing (NGS) panels and cytogenetics provide limited or inconclusive results.

In this webinar, Madina Sukhanova, assistant professor of pathology at Northwestern University Feinberg School of Medicine, will discuss the importance of CMA in oncology testing through a series of representative cases. These illustrative cases will demonstrate the utility of CMA combined with NGS assays to identify genetic aberrations associated with specific prognoses in different types of cancer.

Learning objectives:

  • Learn how to investigate interesting oncology cases and findings.
  • Gain a working knowledge of the importance of CMA and how it plays a vital role in oncology testing.
  • Discover the utility of CMA combined with NGS.

Sponsored by

Feb
22
2022

Sponsored by PGDx

Applying Tumor Homologous Recombination Deficiency in Practice

This webinar is part two of the four part virtual molecular tumor board series.

In this session, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency (HRD).

HRD is known to be a source of risk for heritable malignancies, such as breast and ovarian cancer. Increasing use of genomic sequencing combined with novel clinical development strategies is now expanding the types of cancer that are known to have an HRD subset and may respond to certain treatment regimens. 

Recently, oral PARP inhibitors have been approved, with the greatest activity observed in patients with HRD tumors. While a family of genes implicated in homologous recombination repair (HRR) have been associated with HRD (and related risk of malignancy), the impact of these genes on the activity of PARP inhibitors is still under study. This has increased the clinical challenges for interpretation of next-generation sequencing HRD results for many oncologists, as they try to keep up with which genes to act upon, when to refer a patient for genetic counseling, and how to prioritize HRD-associated therapy with other treatments that may be options based on a patient’s comprehensive genomic profile.

Our panel will address these challenges within the context of specific clinical cases. The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

Sponsored by

PGDx
Feb
11
2022

Sponsored by Natera

Know Cancer’s Next Move: How Circulating Tumor DNA May Serve as a Reliable Biomarker to Predict Recurrence and Aid Patient Stratification

Join us as Dr. Adham Jurdi, Dr. Sakti Chakrabarti, and Dr. Gregory Botta take a closer look at provocative new data surrounding circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment to potentially improve patient management. In this roundtable discussion, panelists will discuss common questions physicians face when treating their gastrointestinal cancer patients including:

  • Are clinicopathological features enough to prognosticate recurrence?
  • How can we use ctDNA to catch relapse earlier and potentially improve patient outcomes?
  • What does the recent data tell us about integrating MRD assays into clinical practice?

Sponsored by

Feb
10
2022

Sponsored by Qiagen

From Information Overload to Actionable Insights: How a National Cancer Research Center Identifies Meaningful Mutations in Somatic Tumor Testing

Precision medicine is transforming cancer care, with next-generation sequencing (NGS) enabling the simultaneous analysis of multiple genomic alterations with therapeutic implications. However, due to the sporadic nature of somatic cancers and the increasing uptake of NGS testing, the number of detected variants is exponentially growing, challenging labs to confidently identify meaningful mutations that could influence or improve decisions at the point of care. Approximately 50 percent of the oncologists in the United States find NGS results sometimes or often difficult to interpret, while 31 percent of small to medium-sized labs in Europe view a lack of knowledge and exposure to routine analyses and interpretation as the most critical bottleneck in NGS testing [1-2].

In this webinar, Ana Krivokuca will present a real-world use case of how the Institute for Oncology and Radiology of Serbia (IORS), a national cancer research center that provides routine NGS testing for cancer patients, uses the Human Somatic Mutation Database (HSMD) in their NGS testing pipeline to validate, assess, and better understand the clinical significance of detected variants.

A new somatic database from QIAGEN, HSMD combines two decades of expert-curated content with data from over 300,000 real-world clinical oncology cases to provide deep genomic insight into the molecular characterizations of a patient’s tumor. Easy to search with new content added weekly, HSMD enables users to explore key genes or mutations with driving properties or clinical relevance, search for associated treatment options, evaluate secondary findings, and develop customized gene panels.

Attendees will:

  • Learn how IORS uses HSMD to identify actionable variants, analyze complex reports,  evaluate secondary findings, and design custom gene panels.
  • Explore HSMD content and features through a virtual demonstration.
  • Receive a complimentary, five-day trial of HSMD.

Sponsored by

field_file_image_alt_text_value